billHR9791•Event Monday, July 20, 2026Analyzed

To amend the Federal Food, Drug, and Cosmetic Act with respect to the requirements for the small business waiver from device fees related to annual establishment registration, and for other purposes.

Neutral

Summary

HR9791 is a procedural bill that would amend the small business waiver requirements for FDA medical device establishment registration fees. It has been referred to committee with no cosponsors and no text available. The bill is in an early stage with no direct market impact on any publicly traded company.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR9791 is a procedural bill with no direct market impact
  • 2.The bill has zero cosponsors and is at the earliest legislative stage
  • 3.No publicly traded companies are affected by this narrow regulatory amendment

Market Implications

No market implications. This bill does not affect any publicly traded company. The medical device fee waiver for small businesses is irrelevant to large-cap medical device manufacturers ($MDT, $BSX, $SYK, $ABT) that dominate the sector.

Full Analysis

  1. On July 20, 2026, Rep. Scott Perry (R-PA-10) introduced HR9791, a bill to amend the Federal Food, Drug, and Cosmetic Act regarding the small business waiver from device fees related to annual establishment registration. The bill was referred to the House Committee on Energy and Commerce. It has zero cosponsors and no further action history beyond introduction.

  2. The bill does not authorize or appropriate any funding. It is a regulatory amendment that would modify eligibility criteria for a fee waiver. The Congressional Budget Office would need to score any change in fee revenue, but no estimate is available. The mechanism is purely administrative — altering who qualifies for a waiver on FDA registration fees for medical device establishments.

  3. No convergence exists with the provided presidential action on chemical manufacturing regulatory relief. That action addresses EPA stationary source regulations for chemical manufacturers, which is a different policy domain (Manufacturing/Energy) with no connection to FDA device registration fees for small businesses.

  4. Structural winners and losers: None. The bill is too early-stage and narrow to identify specific companies. Medical device fee waivers affect small businesses, not publicly traded companies. Large medical device manufacturers ($MDT, $BSX, $SYK, $ABT) are not impacted because they do not qualify for small business waivers.

  5. Timeline: The bill is at the earliest legislative stage. It must pass the House Energy and Commerce Committee, then the full House, then the Senate, and be signed by The President. No hearings or markups have been scheduled. Passage probability is low for a standalone bill with no cosponsors in a divided Congress.

Key Legislators

Rep. Perry, Scott [R-PA-10]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderSep 18, 2026

Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program

This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.

proclamationSep 8, 2026

Accelerating Access To Veterans' Benefits And Employment Opportunities

This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.

Exec OrderAug 10, 2026

Delivering Gold Standard Childhood Vaccine Recommendations for Americans

This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →